Tumor RNA Transfected Dendritic Cell Vaccines
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00108264 |
Recruitment Status :
Completed
First Posted : April 15, 2005
Last Update Posted : January 21, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostate Cancer | Biological: Tumor RNA transfected dendritic cells | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Official Title: | Tumor RNA Transfected Dendritic Cell Vaccines |
Study Completion Date : | September 2005 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 10 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with a histologically confirmed diagnosis of metastatic prostate cancer stages D1 - D3 are eligible for this study.
- They must not have a history of autoimmune disease, serious intercurrent chronic or acute illness, pulmonary disease, active hepatitis, serologic evidence for HIV, or be receiving corticosteroid or immunosuppressive therapy.
Exclusion Criteria:
- Patients will be excluded from the study if they have received chemotherapy or other forms of immunotherapy in the 6 weeks prior to study entry.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00108264
United States, North Carolina | |
Durham VA Medical Center | |
Durham, North Carolina, United States, 27705 |
ClinicalTrials.gov Identifier: | NCT00108264 |
Other Study ID Numbers: |
CLIN-021-02S |
First Posted: | April 15, 2005 Key Record Dates |
Last Update Posted: | January 21, 2009 |
Last Verified: | May 2007 |
Prostatic Neoplasms Neoplasm Metastasis Immunotherapy Active Dendritic Cells |
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms |
Neoplasms by Site Neoplasms Prostatic Diseases |